Matinas BioPharma Holdings, Inc. Quarterly Costs and Expenses in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Matinas BioPharma Holdings, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2017 to Q2 2024.
  • Matinas BioPharma Holdings, Inc. Costs and Expenses for the quarter ending June 30, 2024 was $5.84M, a 5.2% decline year-over-year.
  • Matinas BioPharma Holdings, Inc. Costs and Expenses for the twelve months ending June 30, 2024 was $23.8M, a 8.29% decline year-over-year.
  • Matinas BioPharma Holdings, Inc. annual Costs and Expenses for 2023 was $24.9M, a 10.5% decline from 2022.
  • Matinas BioPharma Holdings, Inc. annual Costs and Expenses for 2022 was $27.8M, a 12.2% increase from 2021.
  • Matinas BioPharma Holdings, Inc. annual Costs and Expenses for 2021 was $24.8M, a 1.65% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $23.8M $5.84M -$320K -5.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $24.1M $5.9M -$780K -11.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $24.9M $5.89M -$656K -10% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 $25.5M $6.13M -$391K -5.99% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $25.9M $6.16M -$829K -11.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $26.7M $6.68M -$1.04M -13.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $27.8M $6.54M -$171K -2.55% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 $27.9M $6.53M -$353K -5.13% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $28.3M $6.99M +$2.2M +45.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $26.1M $7.72M +$1.34M +20.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $24.8M $6.71M +$163K +2.48% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 $24.6M $6.88M +$1.18M +20.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $23.4M $4.79M -$977K -16.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $24.4M $6.39M +$39.9K +0.63% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $24.4M $6.55M +$815K +14.2% Oct 1, 2020 Dec 31, 2020 10-K/A 2022-03-11
Q3 2020 $23.5M $5.7M +$1.14M +25% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $22.4M $5.77M +$1.16M +25.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $21.3M $6.35M +$2.24M +54.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $19M $5.74M +$1.57M +37.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-29
Q3 2019 $17.4M $4.56M +$1.61M +54.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $15.8M $4.61M +$1.12M +31.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $14.7M $4.1M -$47.6K -1.15% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $14.8M $4.17M -$509K -10.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 $15.3M $2.95M -$499K -14.4% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 $15.8M $3.49M -$526K -13.1% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $16.3M $4.15M -$352K -7.81% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q4 2017 $16.7M $4.68M Oct 1, 2017 Dec 31, 2017 10-K 2019-04-01
Q3 2017 $3.45M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $4.02M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $4.5M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.